Guillain-Barre Syndrome can cause profound residual fatigue. I know: I am a survivor. Taking extra potassium improves my muscle strength. Without it, I have weakness that becomes tremors at its worst.
For three years – from 1997 to 2000 – I ate one 200-gram can of salmon a day, literally. By accident, I had discovered that salmon settled a symptom of forceful (but slow) heartbeat which worsened when I lay down and disrupted sleep. This symptom later proved to be a mere side-effect of a new prescription (felodipine, a calcium-channel blocker) which treats pre-syncopal dizziness.
During those years I noticed that my regular salmon meals also improved my muscle stamina. At the time, I assumed the useful ingredient was protein, though it was a conundrum: Why should salmon work so much better than other proteins (beef or chicken) in boosting my muscle stamina?
Before 2000, cans of salmon bore a simple label saying only Ingredients: salmon, water, salt.
From 2000 onward, nutrition labels on food became more detailed. In particular, the tall economy-size can of salmon began to list vitamins and minerals along with the basics. Studying the new label, I noticed a high potassium content (image, left).
According to the label, one-sixth of the can contains 236 grams of potassium. Therefore half the can – the amount I consumed daily – provided 708 grams of potassium.
My physician agreed that potassium could improve forceful heartbeat, but he could not explain why this mineral would improve muscle fatigue from Guillain-Barre Syndrome.
Still, the idea percolated in the back of my mind. For several more months I ‘did the salmon thing’ (by now such a chore that I bypassed plates, spooning it straight from can to mouth). Finally I tried this experiment: I bought Potassium Gluconate tablets over-the-counter and took that in place of salmon. It worked. Potassium alone restored a degree of muscle strength. What a relief: I like the flavor of salmon, but after three years felt utterly saturated with it.
Before taking a potassium supplement, seek your doctor's advice on these points:
My own lab tests verify I need the supplement. Refer to the table below. Note: different labs use different equipment and techniques; it is important to use the units, and the normal or reference range, printed on your own personal lab report.
|Gamma-Dynacare Lab Saskatoon, Canada||Normal range for Potassium: 3.5 to 5.1 mmol/L|
|When I take Potassium Gluconate tablets daily||My blood potassium varies between 3.6 to 4.2 mmol/L
The result is low-normal (inside normal range, but at very low end)
|When I am not taking the supplement||My blood potassium quickly goes down to 3.2 mmol/L
The result is below normal
Potassium supplements are useful and necessary for me. The question is why – what process causes me to lose the potassium I have in my body, and why do I need so much replacement? Neurology researcher Dr. Gareth J. Parry may have an answer.
In January 2010, the US Food and Drug Administration (FDA) approved dalfampridine to treat walking impairment in patients with Multiple Sclerosis (MS). Dalfampridine, a potassium channel blocker, proved in clinical trials that it improved walking speeds. It is the first prescription approved to treat the ongoing disability. Previously, MS treatments were aimed at reducing the relapse rate of the disease.
The most common form of Guillain-Barre Syndrome is Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP). Inflammatory cells and anti-ganglioside antibodies dissolve the myelin sheath (Schwann cells) and sometimes the axon of peripheral nerves. The disease progresses swiftly, reaches a plateau after 2 to 4 weeks, then is followed by a recovery phase where the peripheral nerves regrow at a rate of about one inch per month.
The received wisdom is that Guillain-Barre patients who incompletely recover are those with more severe damage to the axon, since axonal repair is a slower and less effective process than myelin repair.
But that does not explain persistent observations. Research neurologist Dr. Gareth J. Parry says: Some patients exhibit residual slowing of the conduction speed of electrical impulses, the hallmark of incomplete repair of the myelin sheath, even years after the initial event. The degree to which this reduces efficiency of nerve and muscle function is not completely known.
Residual fatigue has a serious impact on the lives of Guillain-Barre survivors. Nearly 80% of patients report disabling fatigue; a smaller percentage report residual weakness or sensory loss. Parry believes these symptoms could be related to incomplete remyelination which reduces the efficiency of electrical impulse transmission.
According to Parry: The chemical 4-amino-pyridine (4-AP) improves nerve conduction in the central nervous system (CNS) in experimental studies. It works by blocking the potassium channel in the wall of the axon. In incompletely remyelinated axons the potassium channels are exposed, allowing potassium to leak out of the axon. Even if the core axon is intact, the myelin wrapping the axon is sufficiently changed to impair the nerve's ability to conduct electrical impulses.
The chemical 4-AP partially prevents leakage of potassium and improves nerve conduction. This is the reason why 4-AP, in the form of dalfampridine tablets, improves walking in MS patients. Since MS is characterized by demyelination and incomplete remyelination in the central nervous system, Parry suggests that dalfampridine may also help Guillain-Barre patients with residual fatigue, weakness, or sensory loss due to incomplete remyelination of the peripheral nervous system.
The dalfampridine treatment which helps MS patients may not necessarily apply to Guillain-Barre. MS affects myelinated axons in the central nervous system, while GBS affects myelinated axons in the peripheral nervous system (Schwann cells). The two categories differ in important ways:
MS patients benefit from dalfampridine because it addresses the ways that CNS electrical transmission is known to fail. But there is hope for GBS, says Parry: There is a possibility that 4-AP in the form of dalfampridine could meaningfully improve GBS patients who have incompletely recovered, particularly those in whom fatigue is the most disabling symptom. Clinical trials will be necessary to determine the benefit.
Tuum Est - It Is Up To You
Sculpture Garden / Dumfries, Scotland
All rising to great places
is by a winding stair
Sir Francis Bacon, Essayist
Of Great Place (1625)
Professor Gareth Parry has studied Guillain-Barré Syndrome and its variants for 4 decades at the University of Minnesota. He was keynote speaker at a recent GBS/CIDP Conference in New Zealand.
Said Parry: ‘Pain and fatigue are very common but much under-appreciated features of GBS and CDIP.’
Parry hopes to start a project on the use of a new medicine – dalfampridine – that could potentially improve function in GBS patients who have not completely recovered.
When peripheral muscles remyelinate, burst strength is restored, but patients still suffer a persistent, profound lack of stamina.
Dalfampridine improves physiological function in nerves of Multiple Sclerosis patients. Parry believes it may have a similar benefit in GBS.
Copyright © 2008-2019 Georgena Sil. All Rights Reserved.